Ginkgo Bioworks Holdings, Inc. (DNA)
NYSE: DNA · Real-Time Price · USD
6.95
0.00 (0.00%)
At close: Sep 4, 2026, 4:00 PM EDT
7.05
+0.10 (1.44%)
Pre-market: Sep 8, 2026, 7:00 AM EDT
Ginkgo Bioworks Holdings Revenue
Ginkgo Bioworks Holdings had revenue of $20.16M in the quarter ending June 30, 2026, a decrease of -48.49%. This brings the company's revenue in the last twelve months to $111.86M, down -51.54% year-over-year. In the year 2025, Ginkgo Bioworks Holdings had annual revenue of $170.16M, down -25.06%.
Revenue (ttm)
$111.86M
Revenue Growth
-51.54%
P/S Ratio
3.53
Revenue / Employee
$273,033
Employees
485
Market Cap
468.01M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 170.16M | -56.89M | -25.06% |
| Dec 31, 2024 | 227.04M | -24.41M | -9.71% |
| Dec 31, 2023 | 251.46M | -226.25M | -47.36% |
| Dec 31, 2022 | 477.71M | 163.87M | 52.21% |
| Dec 31, 2021 | 313.84M | 237.18M | 309.40% |
| Dec 31, 2020 | 76.66M | 22.47M | 41.48% |
| Dec 31, 2019 | 54.18M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Puma Biotechnology | 231.24M |
| C4 Therapeutics | 35.04M |
| Arcturus Therapeutics Holdings | 29.37M |
| Evommune | 10.00M |
| Ocugen | 4.58M |
| Inhibikase Therapeutics | 1.00 |
DNA News
- 4 weeks ago - Ginkgo Bioworks downgraded to Hold from Buy at TD Cowen - TheFly
- 4 weeks ago - Ginkgo Bioworks Holdings Earnings Call Transcript: Q2 2026 - Transcripts
- 4 weeks ago - Ginkgo Bioworks Holdings Earnings release: Q2 2026 - Filings
- 4 weeks ago - Ginkgo Bioworks Holdings Slides: Q2 2026 - Filings
- 4 weeks ago - Ginkgo Bioworks Holdings Quarterly report: Q2 2026 - Filings
- 3 months ago - Ginkgo Datapoints, Tangible Scientific, and Inductive Bio Launch ADME-One™: a High-Throughput ADME Platform That Brings Pharmacokinetic Projection Earlier in Drug Discovery - PRNewsWire
- 4 months ago - Ginkgo Bioworks reaffirms 2026 expected total cash burn of ($150M)-($125M) - TheFly
- 4 months ago - Ginkgo Bioworks Holdings Earnings Call Transcript: Q1 2026 - Transcripts